CareDx, Inc. (NASDAQ:CDNA – Get Free Report) CFO Keith Kennedy sold 2,097 shares of the business’s stock in a transaction on Thursday, November 12th. The shares were sold at an average price of $79.29, for a total transaction of $166,271.13. Following the completion of the transaction, the chief financial officer owned 199,147 shares of the company’s stock, valued at approximately $15,790,365.63. This represents a 1.04% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Keith Kennedy also recently made the following trade(s):
- On Thursday, November 5th, Keith Kennedy sold 61,961 shares of CareDx stock. The stock was sold at an average price of $77.82, for a total transaction of $4,821,805.02.
CareDx Stock Performance
CDNA stock opened at $74.56 on Wednesday. The firm has a market cap of $3.92 billion, a PE ratio of 31.20 and a beta of 2.51. The firm’s fifty day moving average is $67.28 and its 200 day moving average is $37.24. CareDx, Inc. has a one year low of $15.22 and a one year high of $90.87.
CareDx (NASDAQ:CDNA – Get Free Report) last released its quarterly earnings data on Thursday, October 29th. The company reported $0.70 earnings per share for the quarter, beating analysts’ consensus estimates of $0.25 by $0.45. The company had revenue of $139.36 million during the quarter, compared to analysts’ expectations of $121.96 million. CareDx had a net margin of 25.86% and a return on equity of 9.74%. The firm’s revenue for the quarter was up 39.3% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.03 earnings per share. Research analysts predict that CareDx, Inc. will post 1.00 earnings per share for the current fiscal year.
Wall Street Analysts Forecast Growth
CDNA has been the topic of a number of analyst reports. Canaccord Genuity Group set a $99.00 target price on CareDx in a research report on Friday, October 30th. Piper Sandler assumed coverage on CareDx in a research note on Wednesday, November 11th. They issued an “overweight” rating and a $100.00 price target for the company. Wall Street Zen cut CareDx from a “strong-buy” rating to a “buy” rating in a report on Saturday, October 31st. Craig Hallum upgraded CareDx from a “hold” rating to a “buy” rating and set a $64.00 price target on the stock in a research report on Monday, August 3rd. Finally, HC Wainwright reiterated a “neutral” rating and set a $46.00 price target on shares of CareDx in a research report on Friday, July 31st. One equities research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and four have given a Hold rating to the company. Based on data from MarketBeat, CareDx currently has an average rating of “Moderate Buy” and a consensus target price of $70.33.
View Our Latest Stock Report on CareDx
Institutional Investors Weigh In On CareDx
Several institutional investors and hedge funds have recently added to or reduced their stakes in CDNA. BlackRock Inc. purchased a new position in CareDx during the second quarter valued at $137,219,000. Bamco Inc. NY acquired a new stake in shares of CareDx in the second quarter valued at about $55,214,000. Amova Asset Management Americas Inc. increased its stake in shares of CareDx by 2.0% during the first quarter. Amova Asset Management Americas Inc. now owns 1,475,126 shares of the company’s stock worth $25,608,000 after purchasing an additional 28,510 shares in the last quarter. Dimensional Fund Advisors LP increased its stake in shares of CareDx by 11.6% during the first quarter. Dimensional Fund Advisors LP now owns 1,461,914 shares of the company’s stock worth $25,375,000 after purchasing an additional 151,934 shares in the last quarter. Finally, Renaissance Technologies LLC increased its stake in shares of CareDx by 7.2% during the first quarter. Renaissance Technologies LLC now owns 1,184,398 shares of the company’s stock worth $20,561,000 after purchasing an additional 79,200 shares in the last quarter.
CareDx Company Profile
CareDx, Inc. is a precision medicine company focused on organ transplantation. It develops and provides diagnostic tests and related services to help clinicians assess transplant recipients and monitor their health over time. Its offerings include AlloSure, a donor-derived cell-free DNA test used to help monitor for organ rejection, and AlloMap, a gene-expression test used in heart transplant care. CareDx also provides histocompatibility testing, clinical tools, and services designed to support patients and transplant care teams.
Featured Articles
- Five stocks we like better than CareDx
- NVIDIA’s Turbulence Could Have Ripple Effects Across Quantum Computing
- Banking on AI: Can Upstart’s New Bank Plan Turn Its Stock Around?
- Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its Year
- The Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to Watch
Receive News & Ratings for CareDx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CareDx and related companies with MarketBeat.com's FREE daily email newsletter.
